Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerDaniel J. Coleman(Oregon Health & Science University), Joshi J. Alumkal(University of Michigan)Scientific ReportsMarch 7, 201910.1038/s41598-019-40518-5Cited by 36SaveCiteExport RISWatch citationsRelated PapersAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study|The Lancet|2010|1.1kTranscriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity|Nature Communications|2022|59LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function|JCI Insight|2023|40